Subcutaneous Daratumumab (DARA) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
  • Kastritis, Efstathios
  • Palladini, Giovanni O.
  • Minnema, Monique C.
  • Wechalekar, Ashutosh D.
  • Jaccard, Arnaud
  • ... Kim, Kihyun
  • 외 24명
Citations

WEB OF SCIENCE

8
Citations

SCOPUS

0
제목
Subcutaneous Daratumumab (DARA) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
저자
Kastritis, EfstathiosPalladini, Giovanni O.Minnema, Monique C.Wechalekar, Ashutosh D.Jaccard, ArnaudLee, Hans C.Sanchorawala, VaishaliMollee, PeterLu, JinSchoenland, StefanGatt, Moshe E.Suzuki, KenshiKim, KihyunCibeira, TeresaBhutani, ManishaBeksac, MeralLibby, EdwardValent, JasonHungria, VaniaRosenzweig, MichaelBumma, NareshHuart, AntoineTran, NamphuongWang, JianpingChen, YupingVasey, Sandra Y.Schecter, Jordan M.Vermeulen, JessicaComenzo, Raymond L.Merlini, Giampaolo
DOI
10.1182/blood-2024-205077
발행일
2024-11-05
유형
Meeting Abstract
저널명
Blood
144
페이지
891 ~ 893